WEBULL

3 Global Penny Stocks With At Least US$400M Market Cap

Simply Wall St · 2d ago

As global markets navigate the complexities of interest rate adjustments and economic uncertainties, investors continue to explore diverse opportunities. Penny stocks, despite their somewhat outdated moniker, remain an intriguing area for those interested in smaller or newer companies. With strong financial underpinnings, these stocks can offer potential growth and stability; this article will highlight several examples that demonstrate such promise.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Rewards & Risks
Cloudpoint Technology Berhad (KLSE:CLOUDPT) MYR0.65 MYR345.54M ✅ 4 ⚠️ 1 View Analysis >
Lever Style (SEHK:1346) HK$1.51 HK$927.78M ✅ 4 ⚠️ 1 View Analysis >
Foresight Group Holdings (LSE:FSG) £4.14 £474.95M ✅ 5 ⚠️ 0 View Analysis >
TK Group (Holdings) (SEHK:2283) HK$2.52 HK$2.11B ✅ 4 ⚠️ 1 View Analysis >
Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ✅ 4 ⚠️ 2 View Analysis >
Angler Gaming (DB:0QM) €0.37 €223.46M ✅ 3 ⚠️ 3 View Analysis >
CNMC Goldmine Holdings (Catalist:5TP) SGD1.09 SGD441.77M ✅ 4 ⚠️ 1 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.52 SGD13.85B ✅ 5 ⚠️ 1 View Analysis >
Integrated Diagnostics Holdings (LSE:IDHC) $0.675 $392.4M ✅ 4 ⚠️ 2 View Analysis >
Begbies Traynor Group (AIM:BEG) £1.115 £179.44M ✅ 6 ⚠️ 1 View Analysis >

Click here to see the full list of 3,641 stocks from our Global Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Guizhou Yibai Pharmaceutical (SHSE:600594)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Guizhou Yibai Pharmaceutical Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical products in China with a market cap of CN¥3.18 billion.

Operations: The company's revenue is primarily generated from its operations in China, amounting to CN¥1.91 billion.

Market Cap: CN¥3.18B

Guizhou Yibai Pharmaceutical, with a market cap of CN¥3.18 billion, faces challenges as it remains unprofitable, with losses increasing by 49.4% annually over the past five years. Despite this, its board and management are experienced, and the company has not significantly diluted shareholders recently. The debt-to-equity ratio has improved from 47.6% to 33.6% over five years, supported by short-term assets covering both short- and long-term liabilities comfortably. Recent earnings showed a net loss reduction from CN¥169.15 million to CN¥86.56 million year-over-year for nine months ending September 2025, indicating some progress in financial management despite ongoing profitability issues.

SHSE:600594 Debt to Equity History and Analysis as at Dec 2025
SHSE:600594 Debt to Equity History and Analysis as at Dec 2025

Wenfeng Great World Chain Development (SHSE:601010)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Wenfeng Great World Chain Development Corporation operates a commercial retail chain in China with a market cap of CN¥5.40 billion.

Operations: The company's revenue is derived entirely from its operations in China, totaling CN¥1.69 billion.

Market Cap: CN¥5.4B

Wenfeng Great World Chain Development, with a market cap of CN¥5.40 billion, faces challenges as earnings have declined by 14.7% annually over the past five years. Despite having more cash than debt and covering interest payments comfortably, its short-term assets fall short of liabilities. The company's return on equity is low at 2.5%, and recent earnings show a significant drop in net income from CN¥69.37 million to CN¥16.99 million year-over-year for nine months ending September 2025, reflecting ongoing profitability struggles amidst stable management tenure and an inexperienced board of directors.

SHSE:601010 Debt to Equity History and Analysis as at Dec 2025
SHSE:601010 Debt to Equity History and Analysis as at Dec 2025

Dezhan Healthcare (SZSE:000813)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Dezhan Healthcare Company Limited focuses on the research, development, manufacture, and sale of cardiovascular and cerebrovascular drugs in China, with a market cap of CN¥8.07 billion.

Operations: Dezhan Healthcare Company Limited has not reported specific revenue segments.

Market Cap: CN¥8.07B

Dezhan Healthcare, with a market cap of CN¥8.07 billion, has experienced a decline in earnings, reporting sales of CN¥277.5 million for nine months ending September 2025 compared to CN¥354.47 million the previous year, and a net loss of CN¥61.03 million from a prior net income of CN¥8.09 million. Despite being unprofitable and having negative return on equity (-2.47%), the company maintains financial stability with short-term assets (CN¥3.2 billion) exceeding both short-term and long-term liabilities significantly, and its debt is well covered by operating cash flow (32.1%). Management shows moderate experience with an average tenure of 2.3 years.

SZSE:000813 Financial Position Analysis as at Dec 2025
SZSE:000813 Financial Position Analysis as at Dec 2025

Turning Ideas Into Actions

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.